ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 22,681 | 28,087 | 32,501 | NaN |
| Total segment operating expenses-Cost Of Goods Sold | 6,286 | 6,154 | NaN | NaN |
| Total segment operating expenses-Clinical | 1,783 | 1,431 | NaN | NaN |
| Total segment operating expenses-Development | 1,726 | 1,373 | NaN | NaN |
| Total segment operating expenses-Medical Affairs | 1,214 | 1,230 | NaN | NaN |
| Total segment operating expenses-Selling And Marketing Expense | 55,959 | 46,342 | NaN | NaN |
| Total segment operating expenses-General And Administrative Expense | 8,377 | 7,365 | NaN | NaN |
| Total segment operating expenses-Share-Based Compensation | 7,423 | 5,737 | NaN | NaN |
| Total segment operating expenses-Other Expense | 58 | -80 | NaN | NaN |
| Total segment operating expenses | NaN | NaN | 85,693 | NaN |
| Interest income | 1,968 | 10,669 | NaN | NaN |
| Loss from operations | NaN | NaN | -53,192 | NaN |
| Interest expense | 2,441 | 2,599 | NaN | NaN |
| Other income, net | NaN | NaN | 2,041 | NaN |
| Income tax (benefit) expense | NaN | -80 | NaN | NaN |
| Net loss | -60,618 | -41,324 | -51,151 | -78,823 |
| Stock-based compensation expense | 7,423 | 5,737 | 5,689 | 10,669 |
| Provision for inventory reserve | NaN | 0 | 0 | 2,160 |
| Depreciation and amortization expense | 397 | 417 | 391 | 559 |
| Accretion on investments, net of amortization | 990 | 1,003 | 1,092 | 3,428 |
| Other non-cash items | -245 | -151 | -186 | NaN |
| Accounts receivable | 839 | -11,177 | 14,007 | 14,375 |
| Inventories | 294 | 9,717 | -963 | 13,232 |
| Operating lease right-of-use asset and lease liability, net | NaN | NaN | -4 | 92 |
| Prepaid expenses and other assets | 524 | -284 | -1,069 | 697 |
| Donation of equipment | NaN | NaN | 0 | 0 |
| Accounts payable and accrued liabilities | 10,315 | -9,064 | 10,964 | 16,981 |
| Contract liability | -61 | -55 | -55 | -240 |
| Net cash and cash equivalents used in operating activities | -44,946 | -43,485 | -47,047 | -80,334 |
| Purchases of short-term investments, available-for-sale | 14,709 | 48,886 | 127,424 | 65,723 |
| Maturities of short-term investments, available-for-sale | 42,500 | 75,000 | 88,500 | 143,500 |
| Payments of milestone obligations under license agreements | NaN | 2,000 | 5,860 | NaN |
| Purchases of property and equipment | 0 | 0 | 197 | 142 |
| Net cash and cash equivalents provided by investing activities | 27,791 | 24,114 | -44,981 | 77,635 |
| Proceeds from term loan, net of issuance costs | NaN | -1,493 | 97,750 | NaN |
| Payment of term loan issuance costs to third parties | NaN | NaN | 761 | NaN |
| Proceeds from milestone obligations met under license agreements recognized as an increase to the financing liability | NaN | 83 | 2,577 | NaN |
| Proceeds from royalties earned under license agreements recognized as an increase to the financing liability | 97 | NaN | NaN | NaN |
| Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan | 62 | 1,780 | 479 | 3,422 |
| Net cash and cash equivalents provided by financing activities | 159 | 1,131 | 100,045 | 3,422 |
| Net decrease in cash and cash equivalents | -16,996 | -18,240 | 8,017 | 723 |
| Cash and cash equivalents at beginning of period | 41,317 | 59,557 | 50,817 | NaN |
| Cash and cash equivalents at end of period | 24,321 | 41,317 | 59,557 | NaN |